We are delivering our strategy through our key strategic priorities and measuring our performance with KPIs
The key performance indicators (KPIs) we measure our performance against are:
$1936m
Group revenueWhy is it a KPI?
This measures our ability to extract value from our product portfolio across our global markets
2017 Performance:
Group revenue decrease of 1% primarily due to price erosion in US generics industry and continued impact of currency headwinds in MENA
$386m
Core operating profitWhy is it a KPI?
This measures our ability to grow revenue, deliver efficiencies and ensure cost control, while maintaining high quality manufacturing facilities
2017 performance:
The decrease in core operating profit reflects challenging market conditions in the US oral generics market and increased competition on certain injectable products
297
Product approvalsWhy is it a KPI?
This measures our ability to successfully execute our product pipeline across the Group
2017 performance:
We maintained a steady pace of product approvals in Injectables and Branded, but Generic approvals were below target
226
Product submissionsWhy is it a KPI?
This measures our R&D capabilities in new product development across the Group
2017 performance
Increased submissions across our MENA markets more than offset lower submissions in Generics
>4600
Employees with more than five years’ serviceWhy is it a KPI?
This measures our ability to retain a talented workforce across the Group
2017 performance
Slight improvement in number of employees with a length of service above five years, reflecting our continued focus on initiatives to retain talented employees
14.9%
Return on invested capitalWhy is it a KPI?
This measures our efficiency in allocating capital to profitable investments
2017 performance
The significant increase in return on invested capital (ROIC) reflects the reduction in our asset value as a result of the revaluation of the West-Ward Columbus business. Using the 2016 asset valuation, ROIC is 9.7%